Development Procurement, Roche (2014-2018)VP, CFO Global Product Development, Roche (2010-2013) Senior Vice President & Managing DirectorDong Joong Kim Senior Vice President & Managing Director, Business Resources Innovation Center, Samsung Biologics (2014-Present)Head of Planning Support Team, Production Technology Institute, Samsung Electronics(2013-2014) Independent directorSeok Woo Jeong Independent Director, Samsung Biologics (2016-Present)Professor, Department of Business Administration, Korea University Business School (1997-Present)Non-standing Member, Korea Accounting Institute (2016-2019) Independent directorSoon Jo Kwon Independent Director, Samsung Biologics(2016-Present)Professor, Department of BioLogical Engineering, Inha University(2013-Present)Chairman, International Cooperation Committee, Institute of Biological Engineering (IBE)(2011-2013) Independent DirectorKun Nyoung Huh Independent Director, Samsung Biologics(2019-Present)Advisor, Pyeong An Lawfirm(2019-Present)Presiding Judge, Seoul Central District Court (2004-2007) Independent Director Eunice Kyunghee Kim Watch the Interview Independent Director, Samsung Biologics (2020-Present)Professor at Law School of Ewha Women's University (2010-Present)Vice president of International Association of Korean Lawyers (IAKL) (2008-Present)Compliance officer of executive vice president & Head of Legal Affairs at Hana Financial Group, Inc. (2008-2010) Appointment of DirectorsMembers of the board of directors are elected through a resolution of the general meeting of shareholders under the company’s articles of incorporation. Incumbent members may be reelected after the expiration of their terms. Samsung Biologics shall have at least three but no more than ten directors and such directors shall be appointed at the general meeting of shareholders; provided, however, that at least three independent directors shall be appointed and the number of the independent directors shall account for at last a majority of the total number of directors.A resolution for the election of directors shall be adopted by the affirmative votes of a majority of the shareholders present at the meeting, which shall also be at least 1/4 of the total number of issued and outstanding shares.Any vacancy in the office of directors shall be filled at a general meeting of shareholders; provided, however, that if the number of directors does not fall below the number prescribed in Paragraph 1 of Article 29 in the Articles of Incorporation and there is no difficulty in the administration of business, the foregoing shall not be applicable. Term of Office of DirectorThe term of office of directors shall end at the close of the ordinary general meeting of shareholders convened in respect to the last fiscal year within three years from their appointment. ChairpersonThe chairperson of the board of directors shall be appointed among the directors by a resolution of the board of directors. Resolution of the BODThe resolution of the board of directors shall be adopted in the attendance of a majority of the directors in the office and by the affirmative votes of a majority of the directors present at the meeting; provided, however, that a resolution of the board of directors on matters stipulated under Article 397-2 (Prohibition of Use of Corporate Opportunities and Assets) and Article 398 (Self-Dealing between Directors, etc. and the Company) of the Commercial Code shall be adopted by the affirmative votes of at least 2/3 of the directors in office. Independence of Independent DirectorsThe Independent Director Candidate Nomination Committee shall nominate the candidates for the independent directors among persons who meet qualification requirements stipulated in the relevant laws and regulations, including the Commercial Code, etc. An independent director shall be one with professional knowledge or sufficient experience in management, e

development relating to pharmaceutical products, subcontracting, advisory service;6.Education service and business service;7.Research service and investment business;8.Bioengineering and bio-pharmaceutical product research;9.Health and medical research;10.Joint research with domestic or international institutions;11.Technical research service for other domestic or international institutions;12.Plant design, purchasing agency, manufacture, construction, validation and supervision service;13.Real estate sale and purchase and leasing business;14.Transportation business;15.Parking lot business;16.Warehousing business;17.Businesses related to, necessary for, or incidental to any of the foregoing. Article 3 (Location of Head Office and Establishment of Branch, etc.) The Company shall have its head office in Incheon City and, if necessary, may establish branches, representative offices, business offices, sales offices, or local subsidiaries by a resolution of the Board of Directors (BOD) or of such a committee as authorized by the BOD. Article 4 (Method of Public Notices) The Company’s public notices shall be published in the Company’s website (http://samsungbiologics.com); provided, however, that in the event the public notices cannot be posted electronically due to computer system error or other unavoidable circumstances, the public notices shall be published in the JoongAng Ilbo, a daily newspaper of general circulation published in Seoul. Chapter 2.Shares Article 5 (Total Number of Shares Authorized to be Issued) The total number of shares that the Company is authorized to issue shall be Five Hundred Million (500,000,000) shares. Article 6 (Par Value per Share) The par value of each share to be issued by the Company shall be Two Thousand Five Hundred (2,500) won. Article 7 (Total Number of Shares to be Issued upon Incorporation) The total number of shares to be issued at the time of incorporation of the Company shall be One Million Five Hundred Thousand (1,500,000) shares. Article 8 (Classes of Shares and Share Certificates) ①The classes of shares to be issued by the Company shall be common shares and preferred shares, each of which shall be in registered form.②Preferred shares to be issued by the Company shall be preferred shares concerning dividends with non-voting rights, and the number of the preferred shares shall not be more than Fifty Million (50,000,000) shares.③Dividends on the preferred shares shall be first paid in cash at such dividend rate as determined by the BOD or such a committee as authorized by the BOD at the time of issuance based on the par value of the preferred shares.④In the event that the dividend rate of the common shares exceeds that of the preferred shares under Paragraph 3, any excess amount available for distribution after payment of dividends on the preferred shares and the common shares at the same ividend rate as that for the preferred shares shall be equally distributed to both common and preferred shareholders in proportion to their shareholding.⑤In the event that preferred dividends are not fully distributed on the preferred shares for any given fiscal year, any accumulated undistributed dividends shall be preferentially distributed first at the time of distribution of dividends in the immediately following fiscal year.⑥In case of rights issues, bonus issues or stock dividends, common shareholders shall be entitled to common shares, and preferred shareholders shall be entitled to preferred shares, in proportion to their respective shareholding; provided, however, that in case of rights issues, bonus issues or stock dividends, the Company may, if necessary, issue only one class of shares, where all the shareholders shall be entitled to such class of shares to be issued. Article 8-2(Electronic Registration of Rights to be Indicated on Shares and Stock Warrant Certificates) The Company shall electronically register rights to be indicated on shares and stock warrant certificates i

Development- And others Communication Communicate to - Client- Staff- Regulatory Agency- Audit committee- Others BCMO The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. Annual Operation Embedding BCMS is the ongoing cycle of activities of the business continuity management program, which builds organizational resilience, and is the professional practice that defines how to integrate business continuity awareness and practice into business as usual activities. Embedding BCMS Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an incident · Performing Risk and Threat Mitigation Measures Implementation - Implements the solutions agreed in the designed stage · Development of Tactical/Operational Business Continuity Strategy· Establishment of Business Continuity Plans & a response structure Validation - Confirms that the business continuity program meets the objectives set in the policy and the plans and procedures in place are effective. · Exercise Program: performing annual exercises with various types of scenario by each department as well as company-wide· Management Review to ensure it aligns with organizational objectives Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an incident · Pe

development capabilities, we expect to have our portfolio leadership expanded continuously by pursuing a more flexible and accelerated growth strategy. As an extension of our efforts for sustainable management that began in earnest in 2021, we published our second annual ESG report on July 11th to address a wide range of environmental, social, and governance (ESG) activities that had been carried out in the past year in addition to outlining our plans for the upcoming year. Under our mission of ‘Driven. For a Sustainable Life.', we are continuously improving and committing our resources to create a more sustainable environment, build a healthier society, and implement responsible business activities. We will be steadfastly committed to a wide range of socially and environmentally equitable practices to contribute to society with sustainable growth and development. With our pre-emptive and bold investments backed by solid business execution, Samsung Biologics will continue our path forward from the world's best contract development and manufacturing organization (CDMO) to a fully integrated global bio-pharmaceutical company. I would like to express my deepest gratitude for your consistent interest and trust in Samsung Biologics, and greatly appreciate your continued faith and encouragement to support the perpetual growth and sustainable development of all of our businesses. As always, thank you for your support. Sincerely, John Rim President & CEO, Samsung Biologics

development capabilities and its future growth plans, including novel drug development, etc. SUC CE Thanks to the strong support and interest from shareholders and investors, Samsung Biologics successfully completed the rights offering. In return, we will continue our efforts to take a great leap forward to diversify our business portfolio for sustainable growth and ultimately become a global biopharmaceutical company with great responsibilities to better serve our clients, shareholders, and ultimately society. We greatly appreciate your continued support and interest in Samsung Biologics. Thank you Sincerely, John Rim President and CEO, Samsung Biologics

development capabilities and future performance in novel drug development, and the deal will further deliver Samsung Bioepis' sales growth and operating margin improvements with streamlined operational efficiencies, budget surplus, and cash flow generation. We will continue to be in close communication with Biogen to work collaboratively for our future growth together. For the purchase of Bioepsis shares and to fund the company's strategic growth plans, we have decided to raise the capital of KRW 3 trillion by issuing new shares. By expanding our portfolio, we will evolve to become a global biopharmaceutical company as the next growth engine with great responsibilities to better serve our clients, shareholders, and ultimately society. Our company continues to hold the world's largest biomanufacturing capacity since 2019 and is advancing forward through active investment with unparalleled innovation. We are currently building Plant 4 and will begin construction of Plant 5 this year, which will offer multi-modal product services, venturing into expanding business portfolio for cell and gene therapies and next-gen vaccines utilizing mRNA, PDNA and viral vectors, all at a single site, in addition to mRNA DP and DS manufacturing. We are also in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site. At a time of great momentum for change and advancement, your continued support is indispensable. We ask for your continued trust and support for the success of Samsung Biologics. Thank you. Sincerely, 2022.1.28 CEO and President of Samsung Biologics John Rim